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Carle F. Paul5
Although the demand for evidence-based decisions is increasing in clinical practice, recent systematic reviews
on the accuracy of existing psoriasis severity scales, including the Psoriasis Area and Severity Index (PASI),
suggest that their validity is not fully characterized. We simulated the evaluation of PASI by two practitioners in
1,000 sets of 100 patients. PASI data from several practitioners who examined the same patients were used to
generate PASI scores by two practitioners, in order to compare how well commonly used statistics assess the
inter-rater agreement for the PASI. Because the PASI score has an asymmetric distribution, statistics such as
Pearson’s linear correlation coefficient ‘‘r’’ and Spearman’s rank correlation coefficient overestimated the inter-
rater agreement of PASI as compared with the intra-class correlation coefficient (ICC; r¼ 0.8, r¼ 0.7, ICC¼ 0.5).
When restricting the analysis to patients with a PASI o20, inter-rater agreement severely decreased (r¼ 0.38,
r¼ 0.41, ICC¼ 0.17), resulting in unacceptable therapeutic decision agreement (k¼ 0.38). Our study indicates
that owing to the skewed distribution of the PASI its validity to influence therapeutic decisions is questionable.
The ICC is preferable to the commonly used statistics (r and r) for assessing the inter-rater agreement reliability
of asymmetrically distributed scores such as the PASI.
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INTRODUCTION
Two recent comprehensive systematic analyses of the
literature on the accuracy of the existing methods assessing
the clinical severity of psoriasis are available (Puzenat et al.,
2010; Spuls et al., 2010). Many discussions are currently
being held to draw attention to the validation of scoring
methods (Jensen et al., 2011). Although clinical practice
demands evidence-based decisions, a standardized assess-
ment of psoriasis severity is still not available. It appears that
none of the severity scores used for psoriasis meets all of the
validation criteria required for an ideal score. Furthermore,
the statistical methods used in many studies are not fully
appropriate, for example, linear correlation is sometimes
misinterpreted as inter-rater agreement (Puzenat et al., 2010).
In addition, it remains to be determined whether the current
severity score fully addresses patients’ true disease burden in
psoriasis. Standardized quantification of psoriasis severity is
important for patient assessment. In addition, changes in
severity scores are used to evaluate response to therapy.
Current guidelines tend to categorize psoriasis patients
according to PASI, with moderate to severe patients having
PASI scores above 10 or 12 (Nast et al., 2006; Pathirana et al.,
2009). Unfortunately, the reporting of the measurement
validity of PASI is far from being appropriate, and its validity
remains questionable both as a global summary score of
psoriasis severity and as a tool to decipher categories of
patients to adapt treatment.
There has been considerable debate in the literature
regarding the most appropriate method to assess the efficacy
of treatment in psoriasis (Ashcroft et al., 1999). The large
number of parameters used in previous trials highlights the
difficulty of assessing clinical outcome (Ashcroft et al., 1999;
Naldi et al., 2003). In recent years, the Psoriasis Area And
Severity Index (PASI) has become the most popular tool to
categorize patient severity and to assess the efficacy of
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therapeutic interventions in psoriasis (Krueger et al., 2000).
Although complete clearance of psoriasis should be pursued,
it is often an elusive goal, not realized with most therapies.
Frequently, therapeutic effect is expressed as a percentage
reduction of the baseline PASI, with the achievement of
90, 75, and 50% reduction in PASI regarded as clinically
significant (Fredriksson and Pettersson, 1978; Al-Suwaidan
and Feldman, 2000). The PASI was developed more
than 30 years ago and used extensively in clinical trials.
However, it has never been fully validated, and there is
limited information on the clinical significance of a
certain reduction in the score over time (Exum et al., 1996;
van de Kerkhof, 1997; Weisman et al., 2003). In the present
study, we critically assess the limitations in PASI validity and
demonstrate that its inter-rater reliability is overrated, espe-
cially in patients with low to moderate PASI values.
RESULTS
Distribution of the simulated PASI
The distribution of the PASI score in the simulated population
of psoriasis patients is shown in Figure 1. The mean PASI
score is 15.7, with a median of 13.3. Whereas PASI scores
can range between 0 and 72, 50% of the simulated scores are
found between 8.3 and 19.8. No departure between the
simulated PASI distribution and the one observed in our
cohort was detected (P¼0.11). The most striking character-
istic of the PASI distribution is its asymmetry. PASI distribu-
tion is skewed to the right, with most patients having PASI
values below 20. Such an asymmetry in the distribution of
a severity scale has methodological implications in the
evaluation of PASI validity. Indeed, because of high values
of PASI, the average score (15.7) is greater than the median
score (13.3). The distribution is quite dispersed around the
average, with a standard deviation of about 10. A PASI o20
represents 75.8% of the data, and 50% of the simulated PASI
scores are found between 8.3 and 19.8.
Inter-rater scoring agreement according to various statistical
methods
When evaluating the inter-rater agreement of PASI for 100
patients randomly drawn from the population, the three most
commonly used statistics (the linear coefficient correlation (r),
the nonparametric Spearman correlation coefficient (r), and
the intra-class correlation (ICC) coefficient (see Table 1 for
definition)) led to different conclusions (Table 2). The
asymmetry of the score results in an overestimation of the
inter-rater agreement for r (r¼0.8) and r (r¼ 0.7), whereas
ICC (ICC¼0.5) better reflects the extent of inter-rater
discrepancy in comparison with the overall dispersion of
the score.
Focusing on PASIo20, discrepancies between raters were
significantly higher as displayed by less favorable inter-rater
agreement measures. r decreased from 0.8 to 0.38, r
decreased from 0.7 to 0.41, and ICC decreased from 0.5 to
0.17. It shows that the asymmetry of the distribution of the
score in patients also results in an overestimation of its
validity for the most commonly encountered PASI scores. In
addition, although often referred to in the literature, the
statistical significances of the measures do not provide an
accurate picture of the inter-rater agreement (P-values
assessing the statistical significance of correlation coefficients
corresponding to null hypotheses, which are not relevant
to inter-rater agreement issue: r¼ 0, r¼ 0 in Table 1).
Rather than P-values, actual estimations of r, r, or ICC,
and their corresponding confidence intervals are much
more meaningful and can be used to evaluate the extent of
the agreement. As indicated in Table 2 and as confirmed
by the 1,000 additional simulations (Figure 3), ICC is
the only appropriate numerical measure of inter-rater
agreement.
Graphical display of the inter-rater agreement according to
Bland and Altman
Graphical display of inter-rater agreement according to the
Bland and Altman method is the most appropriate
graphical representation of the inter-rater agreement for
severity scale (Figure 2). On the x axis, the average score
given to a patient is plotted. On the y axis, the difference
between the score given by practitioners 1 and 2 is plotted.
The Bland and Altman figure suggests that (1) compared
with practitioner 1 an overestimation by practitioner
2 occurs on the lower scores, whereas (2) practitioner
2 underestimates the most severe patients. No matter how
good the linear correlation between the scores is, severity
assessment may differ quite extensively from one practi-
tioner to another.
Inter-rater decision agreement
Finally, we evaluated the influence of discrepancies in inter-
rater agreement for PASI scores on patient categorization and
therapeutic decision. As disclosed by the analysis, when
therapeutic decision is driven by the PASI with an arbitrary
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Figure 1. Distribution of the simulated PASI scores. The histogram presents
the distribution of the simulated 1,000 PASI scores. Similar to real PASI scores
that combine the assessment of the severity of lesions and the area affected
into a single score, its range is from 0 (no disease) to 72 (maximal disease).
The distribution is asymmetric with a tail for high values of PASI. PASI,
Psoriasis Area and Severity Index.
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cutoff of 12, frequently used in clinical trials, the differences
in inter-rater agreement may have clinical consequences.
As shown in Table 3, in our example 31/100 therapeutic
decisions would be discordant between the two observers.
The Cohen’s k-concordance measure shows that the poor
inter-rater scoring validity of the PASI results in weak
concordance (k¼0.33, 95% confidence interval (0.15;
0.51)) in decision to treat. Such a concordance would
nevertheless reach ‘‘statistical significance’’. As already noted
for the P-values associated with r, r, or ICC, the statistical
significance (testing the null hypothesis of full independence
between raters k¼ 0) is poorly relevant to evaluate agreement
per se. k-Estimations can be qualified as ‘‘statistically
significant’’, but what matters is the excess of agreement
compared with the one occurring by chance. In decision to
treat, a high inter-rater agreement within the most common
disease severity range (PASI: 0–20) is more important than an
overall good correlation between raters. This correlation is
overestimated because of patients with PASI420. In Figure 3,
we confirmed in 1,000 simulations using k-based analysis of
treatment agreement that the use of r and r rather than ICC
can hide variability in a more focused range of the scores
where therapeutic decision matters and for which inter-rater
agreement reliability should not vary.
DISCUSSION
In this study, we used a simulated example to underline the
limited validity of the PASI score for the most commonly
encountered expression of psoriasis. Considering the asym-
metry of PASI score general distribution, the validity of the
PASI is overrated because of the contribution of the high
scores reached by the rare but most severe patients. Such an
observation holds true for any skewed scale used in a clinical
trial, as well as in clinical practice.
As previously noted, an ideal score should use its full
range (Mrowietz et al., 2011). One classical way to address
this issue is to use mathematical transformations of the score
(log transformation, box-cox, or simply reversing the skew-
Table 1. Overview of commonly used statistics to evaluate inter-rater agreement in scoring
Inter-rater
agreement
Index
notation
Question
addressed
Translation of the
statistical model
Adequacy of the
statistics
Commonly admitted
ranges
Scoring agreement for
a patient evaluated by
two different
practitioners?
r/r2 Is there a linear relation
between the evaluations
performed by the two
practitioners?
Existence of a linear
relation between
raters (Y=a  X + b)
+ 40.8: Good
0.5–0.8: Average
o0.5: Poor
Rho (r) Is there consistency between
the hierarchies proposed by
the two evaluations by the
two practitioners?
Conservation of the
severity rank
++ 40.8: Good
0.5–0.8: Average
o0.5: Poor
ICC Is there a lot of variation in
the two evaluations
compared with the overall
variation between patients?
Inter-rater variance/
between-subject
variance
+++ o0.4: Poor
0.4–0.75: Average
40.75: Strong
Table 2. Comparison of the linear parametric r, the rank nonparametric (q), and the ICC coefficients between
practitioner assessment and their statistical significance in the data set
All PASI PASI o20
Correlation statistics Correlation coefficient Confidence interval P-value Correlation coefficient Confidence interval P-value
r 0.8 0.71–0.86 o0.001 0.38 0.17–0.56 o0.001
Rho (r) 0.7 0.60–0.80 o0.001 0.41 0.19–0.58 o0.001
ICC 0.5 0.11–0.75 0.0077 0.169 0.04 to 0.37 0.0574
The table presents the linear parametric correlation (‘‘r’’) also known as Pearson’s correlation coefficient, the rank nonparametric correlation (‘‘Rho’’)
also known as the Spearman’s correlation coefficient, and the intra-class correlation (‘‘ICC’’) coefficients. Confidence interval is an interval estimate
of the population coefficients assessing the reliability of the coefficient estimate. The thinner the interval, the more reliable the results. The P-value
assesses the statistical significance of the null hypothesis that there is no correlation between practitioners assessment (it means r=0, r=0, and ICC=0).
For all Psoriasis Area and Severity Index (PASI) scores, the linear correlation coefficient (r=0.8) and nonparametric correlation coefficient (r=0.7)
demonstrate strong correlations between practitioner assessments. These correlations are significant (P-values are very low). So, if we only look at the linear
correlation, we could conclude that practitioner assessments are similar. Considering the individual PASI values, even if assessments are linearly correlated,
it does not mean that practitioners will treat patients similarly. To compare agreements between practitioners, linear correlation is not a good indicator. The
ICC coefficient indicates the reproducibility of quantitative measurements made by different operators on the same unit. So, in the case of PASI assessment
made by two practitioners, ICC is a better indicator of their agreement. ICC is about 0.5, meaning that the agreement between practitioners is not as good as
suggested by linear correlation coefficients. Considering PASI scores under 20 shows that the difference between usual correlation coefficients (r and r) and
ICC is reinforced (P-value indicates that r and r are significantly different from 0, and P-value of ICC indicates the contrary). From the ICC results, we
conclude that for PASIo20, the PASI assessments are not significantly correlated between practitioners (0 is included within the confidence interval and P-
value 45%).
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ness by taking the remaining part of the PASI score (72-PASI)).
Unfortunately, it will not modify the intrinsic skewness of the
score, and in most cases it will leave unchanged inter-rater
agreement statistics based on variance components. Further-
more, scores following a uniform distribution seem more
appropriate to separate patient groups with different degrees
of disease severity. In addition, the higher scores correspond-
ing to the most severe patients may be overrepresented in
patients from university hospitals representing the majority of
participants in clinical trials. This potential recruitment bias
results in an overrepresentation of severe psoriasis compared
with the general population, and may thus increase the
overrating effect arising from the PASI distribution. When
reduction of PASI by 25 of 50% is assessed, only part of the
PASI scale is used and the small area can influence the ability
to detect clinically significant changes. Although compara-
tive effectiveness of drugs may not be affected by the use of
PASI, the resulting increase of measure dispersion coming
from inter-rater variation affects the statistical power of
studies based on PASI.
For the sake of clinical relevance, applied biostatistics
often have to compromise between pure mathematical
modeling and translation into practical matters. Although it
could appear easy to be misled by inappropriate uses of
statistics, our study illustrates the need for appropriate
statistical knowledge and understanding to draw conclusions
useful for evidence-based decision making. As Dermatology
and other clinical sciences move forward and more data are
accumulated, making the field more specialized than ever, it
becomes more important to work trans-disciplinarily and
recall the limitations of the use of statistics to the extent to
which mathematical modeling is capable of reflecting
underlying clinical reality. This simple simulated example
illustrated that r, r, and ICC may perform quite differently.
The use of ICC as the most robust and stringent measure of
inter-rater agreement must be promoted. The data shown
here call for a better integration of biostatistics in initial and
continuous medical education (Windish et al., 2007).
The present study calls for cautious statistical analysis of
score and development of score, which are in line with
current issues. The PASI score has been incredibly useful and
largely used in clinical trial for research purpose. The PASI
may not fulfill the current need for a reliable severity scale to
be used in clinical practice to guide therapeutic decision.
MATERIALS AND METHODS
Simulations of PASI scores
A distribution of the PASI scores of patients was simulated from a
mixture of an exponentially decreasing distribution and a normal
distribution. The distribution was designed to fit the real data set
from an ongoing multicenter French study of 105 patients with
moderate to severe psoriasis who are candidates for treatment with
systemic therapy or biological agents and the abundant literature on
PASI distribution in population. Over 1,000 simulations, 100 PASI
scores were sampled at random. For each of the scores, we
simulated a second one to provide a second score reading as if the
patient’s Psoriasis was measured by two different practitioners. The
second score was simulated using a Gaussian error and fixed-effect
models. In Supplementary Material online (Supplementary Figure S1
online), a simulation scenario based on the sole Gaussian divergence
is shown. In all simulations, scores were constrained to the real PASI
range between 0 and 72. The first set of simulated data are available
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Figure 2. Scatter plot of the average score for an individual patient (x axis)
and the difference between practitioners (y axis), also known as the Bland
and Altman graph. The Bland and Altman graph is used to visualize the
agreement between two different measurements made on the same subjects.
A good agreement is demonstrated by data centered on 0 (dashed line),
meaning that assessments between practitioners are very close. In this case,
even if the confidence interval of the differences average (both dotted lines)
includes 0, we cannot conclude that the agreement between practitioners is
good: data are not centered on 0 (differences average between practitioners is
about 12.55 (bold solid line)) and are not stable regarding the rating average
(differences are increasing with rating average).
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Figure 3. Distributions of the linear parametric (r), the rank nonparametric
(rho (q)), the intra-class correlation (ICC) coefficients between practitioner
assessment, and the Kappa (j)-coefficients observed over 1,000 independent
simulations of an assessment of the PASI score by two practitioners. The
distributions of the four statistics are drawn from 1,000 bootstrap samples of
100 PASI scores coming from the scenario 1. At the top, distributions are
drawn for all PASI scores, whereas at the bottom only PASI scores o20 are
used. Distributions of r and r are very close and quite similar in the case of
PASIo20. r and r distributions are centered on higher values than k and ICC
distributions. For PASI o 20, k and ICC distributions are centered on very
close averages. PASI, Psoriasis Area and Severity Index.
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as Supplementary Material online (Supplementary Figure S1 online),
and all other simulated material will be made available on request.
Evaluation of inter-rater agreement
The distribution of the simulated PASI scores is summarized by means
of a histogram. To illustrate the difficulty of validating the PASI score
raised by its distribution, we took the inter-rater agreement as an
example. For a given patient, PASI scores were simulated for two
practitioners based on real data initially collected to compare PASI
assessment between practitioners (Puzenat et al., 2010) and supported
by inter-rater variability data on PASI assessment studies from the
literature (Kirby et al., 2000, 2001; Langley and Ellis, 2004; Berth-Jones
et al., 2006; Puzenat et al., 2010; Spuls et al., 2010). The PASI scores
simulated were compared using commonly found statistics (although
not appropriate) as reported by Puzenat et al., 2010: Pearson’s linear
correlation coefficient (parametric), Spearman’s rank correlation
coefficient (nonparametric), and ICC. Their definition and properties
are summarized in Table 1. ICC is the only statistic developed for inter-
rater agreement study, as it compares the variability observed between
practitioners 1 and 2 with the overall variability observed between
individuals. These three statistical indexes were computed both for all
PASI values and for PASI values below 20.
Evaluation of inter-rater decision agreement
We compared the agreement of therapeutic decision making based
on PASI evaluation. To this end, we selected a PASI threshold of 12.
It allows investigating the role of inter-rater agreement on the
specific treat/no-treat decision cutoff based on PASI. All simulations
were performed using Stata 10.1 SE (Stata Corp, College Station, TX).
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Treated 51 6 0.33 0.15–0.51 o1e3
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The table presents the contingency table comparing practitioner’s
decision (treatment or not based on PASI above or below 12) and
statistical results coming from k-coefficient estimations. The k-coefficient
indicates the agreement between practitioners about the decision to treat
or not. Confidence interval allows us to estimate the reliability of the
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assumption that there is no agreement between practitioners (meaning k-
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